<?xml version="1.0" encoding="iso-8859-1" ?> 
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/">
	<channel>
		<title>Fishnet NewMedia</title> 
		<link>http://www.ahoy.com/</link> 
		<description>Fishnet NewMedia is a Solutions and Hosting provider specializing in Web and Internet Technology.</description>
		<copyright /> 
		<language>en-us</language> 
		<image>
			<title>Fishnet NewMedia logo</title> 
			<url>http://www.ahoy.com/images/Nav_Logo.gif</url> 
			<link>http://www.ahoy.com/</link> 
			<width>200</width> 
			<height>66</height> 
			<description>Fishnet NewMedia logo</description> 
		</image>
		<item>
<title>WuXi PharmaTech Announces Preliminary Second-Quarter 2010 Financial Highlights and Increases Full-Year 2010 Financial Guidance</title>
<description>WuXi PharmaTech (Cayman) Inc. (NYSE:WX), a leading research and development outsourcing company serving the pharmaceutical,biotechnology, and medical device industries, with operations in China and the United States, today announced its preliminary financial highlights for second-quarter 2010. The full earnings results will be
announced on August 2, 2010.</description>
<link>http://www.fidelitybiosciences.com/news/news_detail.cgi/104/0</link>
<pubDate>Thu, 15 Jul 2010 05:13:00 GMT</pubDate>
<category>News</category>
</item>
<item>
<title>ENVIVO PHARMACEUTICALS ANNOUNCES SIGNIFICANT RESULTS FROM GSM TRANSGENIC MOUSE MODEL FOR ALZHEIMER’S DISEASE</title>
<description>EnVivo Pharmaceuticals today announced at the Alzheimer’s Association 2010 International Conference on Alzheimer’s Disease (ICAD) results from its proprietary gamma-secretase modulator (GSM) pre-clinical study. </description>
<link>http://www.fidelitybiosciences.com/news/news_detail.cgi/105/0</link>
<pubDate>Wed, 14 Jul 2010 05:13:00 GMT</pubDate>
<category>News</category>
</item>
<item>
<title>Accuri Cytometers Completes $6 Million Series E Financing</title>
<description>Accuri Cytometers, Inc., a world leader in providing life science researchers with easy-to-use, cost-effective flow cytometers, today announced completion of a $6 million Series E preferred stock financing. </description>
<link>http://www.fidelitybiosciences.com/news/news_detail.cgi/103/0</link>
<pubDate>Mon, 12 Jul 2010 05:13:00 GMT</pubDate>
<category>News</category>
</item>

	</channel>
</rss>
